Post Hoc Analysis of Rapid and Deep Prostate-specific Antigen Decline and Patient-reported Health-related Quality of Life in SPARTAN and TITAN Patients with Advanced Prostate Cancer.

Apalutamide Metastatic castration-sensitive prostate cancer Nonmetastatic castration-resistant prostate cancer

Journal

European urology oncology
ISSN: 2588-9311
Titre abrégé: Eur Urol Oncol
Pays: Netherlands
ID NLM: 101724904

Informations de publication

Date de publication:
09 Dec 2023
Historique:
received: 15 08 2023
revised: 23 10 2023
accepted: 17 11 2023
medline: 11 12 2023
pubmed: 11 12 2023
entrez: 10 12 2023
Statut: aheadofprint

Résumé

Adding apalutamide to androgen-deprivation therapy (ADT) resulted in a rapid (at 3- and 6-mo treatment) and deep prostate-specific antigen (PSA) decline (to ≤0.2 ng/ml or ≥90% from baseline), improved overall survival, reduced risk of disease progression, and prolonged health-related quality of life (HRQoL) in nonmetastatic castration-resistant prostate cancer (nmCRPC) in SPARTAN and metastatic castration-sensitive PC (mCSPC) in TITAN. To evaluate the association of a rapid, deep PSA decline at 3 and 6 mo achieved with the addition of apalutamide to ADT with patient-reported outcomes (PROs) in SPARTAN and TITAN. A post hoc analysis of SPARTAN and TITAN PRO data was performed. Apalutamide versus placebo plus concurrent ADT. PROs were assessed using Functional Assessment of Cancer Therapy-Prostate (FACT-P; SPARTAN and TITAN), Brief Pain Inventory-Short Form (BPI-SF; TITAN), and Brief Fatigue Inventory (BFI; TITAN) at baseline, prespecified cycles during treatment, and after progression for ≤1 yr. The association between a deep PSA decline at landmark 3 or 6 mo of apalutamide and the time to worsening of PROs was assessed using the Kaplan-Meier methodology and Cox proportional-hazard modeling. Among 806 SPARTAN and 525 TITAN apalutamide-treated patients, the median treatment duration was 32.9 and 39.3 mo, respectively. Patients achieving a deep PSA decline at 3 mo had longer time to worsening in FACT-P total, FACT-P physical well-being, BPI-SF worst pain intensity, or BFI worst fatigue intensity. The 6-mo PSA decline results were similar. Limitations of patient characteristics in clinical studies should be considered. Attaining a deep and rapid PSA decline at 3 mo with apalutamide plus ADT was associated with longer preservation of overall HRQoL and physical well-being in nmCRPC and mCSPC. Quality of life is maintained in individuals with advanced prostate cancer who achieve a deep prostate-specific antigen decline at 3 mo of apalutamide plus drugs that lower male sex hormones.

Sections du résumé

BACKGROUND BACKGROUND
Adding apalutamide to androgen-deprivation therapy (ADT) resulted in a rapid (at 3- and 6-mo treatment) and deep prostate-specific antigen (PSA) decline (to ≤0.2 ng/ml or ≥90% from baseline), improved overall survival, reduced risk of disease progression, and prolonged health-related quality of life (HRQoL) in nonmetastatic castration-resistant prostate cancer (nmCRPC) in SPARTAN and metastatic castration-sensitive PC (mCSPC) in TITAN.
OBJECTIVE OBJECTIVE
To evaluate the association of a rapid, deep PSA decline at 3 and 6 mo achieved with the addition of apalutamide to ADT with patient-reported outcomes (PROs) in SPARTAN and TITAN.
DESIGN, SETTING, AND PARTICIPANTS METHODS
A post hoc analysis of SPARTAN and TITAN PRO data was performed.
INTERVENTION METHODS
Apalutamide versus placebo plus concurrent ADT.
OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS METHODS
PROs were assessed using Functional Assessment of Cancer Therapy-Prostate (FACT-P; SPARTAN and TITAN), Brief Pain Inventory-Short Form (BPI-SF; TITAN), and Brief Fatigue Inventory (BFI; TITAN) at baseline, prespecified cycles during treatment, and after progression for ≤1 yr. The association between a deep PSA decline at landmark 3 or 6 mo of apalutamide and the time to worsening of PROs was assessed using the Kaplan-Meier methodology and Cox proportional-hazard modeling.
RESULTS AND LIMITATIONS CONCLUSIONS
Among 806 SPARTAN and 525 TITAN apalutamide-treated patients, the median treatment duration was 32.9 and 39.3 mo, respectively. Patients achieving a deep PSA decline at 3 mo had longer time to worsening in FACT-P total, FACT-P physical well-being, BPI-SF worst pain intensity, or BFI worst fatigue intensity. The 6-mo PSA decline results were similar. Limitations of patient characteristics in clinical studies should be considered.
CONCLUSIONS CONCLUSIONS
Attaining a deep and rapid PSA decline at 3 mo with apalutamide plus ADT was associated with longer preservation of overall HRQoL and physical well-being in nmCRPC and mCSPC.
PATIENT SUMMARY RESULTS
Quality of life is maintained in individuals with advanced prostate cancer who achieve a deep prostate-specific antigen decline at 3 mo of apalutamide plus drugs that lower male sex hormones.

Identifiants

pubmed: 38072759
pii: S2588-9311(23)00280-8
doi: 10.1016/j.euo.2023.11.015
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2023 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Auteurs

Eric J Small (EJ)

Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA. Electronic address: eric.small@ucsf.edu.

Kim N Chi (KN)

BC Cancer and Vancouver Prostate Centre, Vancouver, BC, Canada.

Simon Chowdhury (S)

Guy's, King's, and St. Thomas' Hospitals and Sarah Cannon Research Institute, London, UK.

Katherine B Bevans (KB)

Janssen Global Commercial Strategy Organization, Horsham, PA, USA.

Amitabha Bhaumik (A)

Janssen Research & Development, Titusville, NJ, USA.

Fred Saad (F)

Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada.

Byung Ha Chung (BH)

Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.

Lawrence I Karsh (LI)

The Urology Center of Colorado, Denver, CO, USA.

Stéphane Oudard (S)

Georges Pompidou Hospital, Université Paris Descartes, Paris, France.

Peter De Porre (P)

Janssen Research & Development, Beerse, Belgium.

Sabine D Brookman-May (SD)

Ludwig-Maximilians-University, Munich, Germany; Janssen Research & Development, Spring House, PA, USA.

Sharon A McCarthy (SA)

Janssen Research & Development, Raritan, NJ, USA.

Suneel D Mundle (SD)

Janssen Research & Development, Raritan, NJ, USA.

Hirotsugu Uemura (H)

Kindai University Faculty of Medicine, Osaka, Japan.

Matthew R Smith (MR)

Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA.

Neeraj Agarwal (N)

Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.

Classifications MeSH